The US Food and Drug Administration (FDA) has approved the novel calcimimetic etelcalcetide (Parsabiv, Amgen) for the treatment of secondary hyperparathyroidism in adults on hemodialysis.

Please provide your email address to receive an email when new articles are posted on . A lower parathyroid hormone target treatment method was linked with reduced adjusted hazard of death. The ...

Please provide your email address to receive an email when new articles are posted on . Adults who underwent Roux-en-Y gastric bypass who were also vitamin D deficient had an increased risk for ...

In a retrospective study, investigators found that radiofrequency ablation and parathyroidectomy for secondary hyperparathyroidism in patients on dialysis achieved intact parathyroid hormone levels in ...

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) had recommended approval of etelcalcetide (Parsabiv, Amgen Europe BV) for the treatment of secondary ...

DUBLIN--(BUSINESS WIRE)--The "Secondary Hyperparathyroidism Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ...

THOUSAND OAKS, Calif., May 29, 2015 -- Amgen (NASDAQ: AMGN) today announced pooled data from two pivotal Phase 3, global, randomized, placebo-controlled trials evaluating AMG 416, a novel calcimimetic ...

Loop diuretics increase the risk of secondary hyperparathyroidism in CKD patients, but concurrent use of thiazide diuretics attenuate that risk. Subjects on loop diuretics had a 2.4 times increased ...

This brief article is a response to the article by Monge et al. on page 326 entitled Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients.

DUBLIN--(BUSINESS WIRE)--The "Secondary Hyperparathyroidism - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. The latest Pharmaceutical and Healthcare ...

SECONDARY hyperparathyroidism associated with chronic renal disease may simulate primary hyper-parathyroidism with secondary renal impairment in virtually every particular. An exception is the brown ...